Journal
JOURNAL OF CLINICAL GASTROENTEROLOGY
Volume 41, Issue 4, Pages 345-351Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.mcg.0000225665.68920.df
Keywords
chloride; chloride channels; constipation; functional bowel disorders; gastrointestinal motility; intestinal secretion; irritable bowel syndrome; lubiprostone
Categories
Ask authors/readers for more resources
In January 2006 the Food and Drug Administration approved lubiprostone for the treatment of chronic constipation in men and women aged 18 and over. Lubiprostone is categorized as a prostone, a bicyclic fatty acid metabolite of prostaglandin E1. Lubiprostone activates a specific chloride channel (ClC-2) in the gastrointestinal (GI) tract to enhance intestinal fluid secretion, which increases GI transit and improves symptoms of constipation. This article reviews the role of chloride channels in the GI tract, describes the structure, function, and pharmacokinetics of lubiprostone, and discusses clinically important data on this new medication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available